Farah A., Tuttle R.: Studies on the pharmacology of glucagon. J Exp Pharm Exp Therap129: 49-55, 1960
2.
Kones RJ, Phillips JH: Glucagon: present status in cardiovascular disease. Clin Pharm Therap: 12: 427-444, 1971
3.
Lucchesi BR: Cardiac actions of glucagon. Circ Res22: 777-787, 1968
4.
Glick G., Parmley WW, Wechsler AS, et al: Glucagon—its enhancement of cardiac performance in the cat and dog and persistance of its inotropic action despite beta-receptor blockage with propranolol. Circ Res22: 789-799, 1968
5.
Regan TJ, Lehan PH, Henneman DH, et al: Myocardial metabolic and contractile response to glucagon and epinephrine. J Lab Clin Med63: 638-647, 1964
6.
Spilker B.: Comparison of the inotropic response to glucagon, ouabain, and noradrenaline . Brit J Pharmacol40: 382-395, 1970
7.
Klein SW, Morch JE, Mahon WA: Cardiovascular effects of glucagon in man. Canad Med Assn J98: 1161-1164, 1968
8.
Parmley WW, Glick G., Sonnenblick EH: Cardiovascular effects of glucagon in man. New Eng J Med279: 12-17,1968
9.
Linhart JW, Barold S., Cohen LS, et al: Cardiovascular effects of glucagon in man. Amer J Cardiol22: 706-710, 1968
10.
Williams JF Jr, Childress RH, Chip JN, et al: Hemodynamic effects of glucagon in patients with heart disease. Circulation34: 38-47, 1969
11.
Cohn KE, Agmon J., Gamble OW: The effects of glucagon on arrhythmias due to digitalis toxicity. Amer J Cardiol25: 683-689, 1970
12.
Whitsitt LS , Lucchesi BR: Effects of beta receptor blockade and glucagon on the atrioventricular transmission system in the dog. Circ Res23: 585-595, 1968
13.
Steiner C., Wit AL, Damato AN: Effects of glucagon on atrioventricular conduction and ventricular automaticity in dogs. Circ Res24: 167-177, 1969
14.
Lucchesi BR , Stutz DR, Winfield RA: Glucagon: its enhancement of atrioventricular nodal pacemaker activity and failure to increase ventricular automaticity in dogs. Circ Res25: 183-189, 1969
15.
Moir G., Nayler WG: Coronary vascular effects of glucagon in the isolated dog heart. Circ Res26: 29-34, 1970
16.
Goldschlager N., Robin E., Cowan CM, et al: The effect of glucagon on the coronary circulation in man. Circulation40: 829-837, 1969
17.
Manchester JH, Parmley WW, Matloff JM, et al: Effects of glucagon on myocardial oxygen consumption and coronary blood flow in man and in dog . Circulation41: 579-588, 1970
18.
Gorman CK, Carter J., Goldman BS: The effects of glucagon on cardiac dynamics and metabolism. Clin Res18: 713, 1970
Kones, RJ: Glucagon in heart block. Southern Med J64: 459-461, 1971
21.
VanderArk CR , Reynold EW: Clinical evaluation of glucagon by continuous infusion in the treatment of low cardiac output states. Amer Heart J70: 481-487, 1970
22.
Nord HJ, Fontanes AL, Williams JF, Jr: Treatment of congestive heart failure with glucagon. Ann Int Med72: 649-653, 1970
Kones RJ, Phillips JH: Newer inotropic agents for cardiogenic shock. Southern Med J65: 329-332, 1972
25.
Parmley WW, Sonnenblick EH: Glucagon: a new agent in cardiac therapy. Amer J Cardiol27: 298-303, 1971
26.
Wilcken Del, Lvoff R.: Glucagon in resistant heart-failure and cardiogenic shock. Lancet2: 1315-1318, 1970
27.
Eddy JD, O'Brien ET, Singh SP: Glucagon and haemodynamics of acute myocardial infarction. Brit Med J4: 663-665, 1969
28.
Robert M., Humair L.: Effet cardiotonique du glucagon. Schweiz med Wschr100: 1345-1352, 1970
29.
Murtagh JG, Binnion PF, Lal S., et al: Haemodynamic effects of glucagon. Brit Heart J32: 307-315, 1970
30.
Gregory J., Mueller H., Gnoj J., et al: Effects of glucagon on cardiovascular dynamics and myocardial metabolism in the low cardiac output state. Clin Res17: 243, 1969
31.
Greenberg BH , Tsakiris AG, Moffitt EA: The hemodynamic and metabolic effects of glucagon in patients with chronic valvular heart disease. Mayo Clin Proc45: 132-139, 1970
32.
Amsterdam EA , Zelis R., Spann JF Jr, et al: Cardiocirculatory effects of glucagon in patients with congestive heart failure and cardiogenic shock. Amer J Cardiol25: 82, 1970
33.
Puri PS, Bing RJ: Effects of glucagon on myocardial contractility and hemodynamics in acute experimental myocardial infarction. Basis for its possible use in cardiogenic shock. Amer Heart J78: 660-668, 1969
34.
Manchester JH, Parmley WW, Matloff J., et al: Beneficial effects of glucagon in canine myocardial infarction and shock. Clin Res17: 252, 1969
35.
Haddy FJ: Pathophysiology and therapy of the shock of myocardial infarction . Ann Int Med73: 809-827, 1970
36.
Braunwald E. : The determinants of myocardial oxygen consumption . The Physiologist12: 65-93, 1969
37.
Diamond G., Forrester J., Danzig R., et al: Left ventricular failure in acute myocardial infarction, hemodynamic effects of glucagon. Clin Res18: 304, 1970
38.
Levey GS, Prindle KH Jr, Epstein SE: Effects of glucagon on adenyl cyclase activity in the left and right ventricles and liver in experimentally-produced isolated right ventricular failure. J Mol Cell Cardiol1: 403-410, 1970
39.
Gold HK, Prindle KH, Levey GS, et al: Effects of experimental heart failure on the capacity of glucagon to augment myocardial contractility and activate adenyl cyclase. J Clin Invest49: 999-1006, 1970
40.
Schorr I., Ney RL: Ectopic adenyl cyclase receptors in adrenocortical cancer. Clin Res19: 69, 1971
41.
Rodbell M., Birnbaumer L., Pohl SL: Adenyl cyclase in fat cells. III. Stimulation by secretion and the effects of trypsin on the receptors for lipolytic hormones. J Biol Chem245: 718-722, 1970
42.
Kono T.: Destruction and restoration of the insulin effector of isolated fat cells . J Biol Chem244: 5777-5784, 1969
43.
Lefer AM: Role of a myocardial depressant factor in the pathogenesis of circulatory shock. Fed Proc29: 1836-1847, 1970
44.
Thalinger AR , Lefer AM: Cardiac actions of a myocardial depressant factor isolated from shock plasma. Proc Soc Exp Biol Med136: 354-358, 1971
45.
Motsay GJ, Schultz LS, Dietzmann RH, et al: Pharmacologic versus mechanical support for "pump failure." Amer J Cardiol26: 650-651, 1970
46.
Shubin H., Weil MH: Practical considerations in the management of shock complicating acute myocardial infarction. A summary of current practice. Amer J Cardiol26: 603-608, 1970
47.
Matloff JM, Parmley WW, Manchester JH, et al: Hemodynamic effects of glucagon and intraaortic balloon counterpulsation in canine myocardial infarction. Amer J Cardiol25: 675-682, 1970
48.
Braunwald E. : On the difference between the heart's output and its contractile state. Circulation43: 171-174, 1971
